Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.56 |
| ▸ | LIMK1 | P53667 | 4/20 | 0.55 |
| ▸ | LIMK2 | P53671 | 3/20 | 0.55 |
| ▸ | HTR6 | P50406 | 6/20 | 0.55 |
| ▸ | GHSR | Q92847 | 2/20 | 0.55 |
| ▸ | MLNR | O43193 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | WDR5 | P61964 | 1/20 | 0.52 |
| ▸ | RARB | P10826 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3553788 | 0.94 | POLB (0.57) | METAP2LIMK1LIMK2HTR6GHSR | |
| SCHEMBL3555871 | 0.92 | POLB (0.60) | LIMK1LIMK2HTR6POLB | |
| SCHEMBL3561244 | 0.91 | ALDH1A1 (0.57) | LIMK1LIMK2HTR6POLB | |
| SCHEMBL3550679 | 0.91 | WDR5 (0.57) | LIMK1LIMK2GHSRPOLBWDR5 | |
| SCHEMBL3555360 | 0.89 | FFAR1 (0.59) | METAP2LIMK1LIMK2HTR6GHSR | |
| SCHEMBL3553771 | 0.88 | CA12 (0.61) | LIMK1LIMK2HTR6POLB | |
| SCHEMBL3556021 | 0.88 | KDM1A (0.59) | LIMK1LIMK2HTR6POLB | |
| SCHEMBL3558350 | 0.88 | FFAR1 (0.67) | METAP2LIMK1LIMK2HTR6GHSR | |
| SCHEMBL3555628 | 0.88 | HTR6 (0.65) | LIMK1LIMK2HTR6KEAP1NFE2L2 | |
| SCHEMBL3565938 | 0.86 | METAP2 (0.59) | METAP2LIMK1LIMK2HTR6GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1761486-A1 | PHENYLCARBOXYLIC ACID DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006000288-A1 | PHENYLCARBOXYLIC ACID DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | METAP2 2438/4885LIMK1 2986/4885LIMK2 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.